Abstract:Colorectal cancer (CRC) is the third leading cause of cancer-associated mortality worldwide. Ginsenoside Rh1 (Rh1) is a traditional medicine monomer with antitumor activity; however, the effects of Rh1 in CRC remain to be determined. In the present study, SW620 cells were treated with different concentrations of Rh1. Cell Counting Kit-8, wound healing and Transwell assays were performed to measure cell viability and proliferation, migration and invasion, respectively. Subsequently, the mRNA expression levels of matrix metallopeptidase (MMP)1, MMP3 and tissue inhibitor of metalloproteinases 3 (TIMP3) were detected by reverse transcription-quantitative PCR analysis. In addition, the protein expression levels of MMP1, MMP3, TIMP3, and total or phosphorylated (p-)ERK1/2, P38, JNK were detected by western blotting. Furthermore, tumor growth was examined in a nude mouse xenograft model. The results of the present study indicated that Rh1 was not toxic to CRC cells at various concentrations (0, 50 or 100 µM) and treatment durations (24 or 48 h). However, cell proliferation was suppressed by Rh1 in a dose-dependent manner. Rh1 (100 µM) significantly inhibited cell migration and invasion in vitro. Additionally, Rh1 suppressed the mRNA and protein expression of MMP1 and MMP3, and promoted TIMP3 expression. Rh1 decreased the ratios of p-P38/P38, p-ERK1/2/ERK1-2 and p-JNK/JNK in vitro and in vivo, which suggested that Rh1 inactivated the mitogen-activated protein kinase (MAPK) signaling pathway. Notably, Rh1 markedly decreased tumor volume and weight in vivo. In conclusion, the present study demonstrated that Rh1 inhibited the proliferation, migration and invasion of CRC cells in vitro and tumor growth in vivo. This inhibition was at least partially due to the inhibition of MMP1 and MMP3 expression, the increase in TIMP3 expression level and the MAPK signaling pathway inactivation. Therefore, Rh1 may effectively inhibit the development of CRC as an anticancer drug, and may have a supporting effect during CRC treatment.

Ginsenoside Rg5 Inhibits Cancer Cell Migration by Inhibiting the Nuclear Factor-Κb and Erythropoietin-Producing Hepatocellular Receptor A2 Signaling Pathways.

Ginsenoside Rg3 Inhibits CXCR4 Expression and Related Migrations in a Breast Cancer Cell Line.

Ginsenoside Rg3 Suppresses Epithelial-Mesenchymal Transition via Downregulating Notch-Hes1 Signaling in Colon Cancer Cells

Ginsenoside Rg3 Attenuates Cell Migration Via Inhibition of Aquaporin 1 Expression in Pc-3m Prostate Cancer Cells

Ginsenoside Rb2 Inhibits Epithelial-Mesenchymal Transition of Colorectal Cancer Cells by Suppressing TGF-β/Smad Signaling.

Ginsenoside 20(S)-Rg3 Suppresses Ovarian Cancer Migration Via Hypoxia-Inducible Factor 1 Alpha and Nuclear Factor-Kappa B Signals.

Ginsenoside Rg3 Inhibit The Proliferation And Metastasis of Cervical Cancer Cells in Vitro By Regulating NF-κB Signaling Pathway

Ginsenoside Rh1 Inhibits Colorectal Cancer Cell Migration and Invasion in Vitro and Tumor Growth in Vivo

Ginsenoside Rh4 Suppresses Metastasis of Gastric Cancer via SIX1-Dependent TGF-β/Smad2/3 Signaling Pathway

Ginsenoside Rg5 Induces G2/M Phase Arrest, Apoptosis and Autophagy Via Regulating ROS-mediated MAPK Pathways Against Human Gastric Cancer.

Ginsenoside Rh1 regulates gastric cancer cell biological behaviours and transplanted tumour growth in nude mice via the TGF-beta/Smad pathway

Ginsenoside Rh4 Suppresses Metastasis of Gastric Cancer via SIX1-Dependent TGF-/Smad2/3 Signaling Pathway

Ginsenoside 20(S)-Rg3 Induced Autophagy to Inhibit Migration and Invasion of Ovarian Cancer.

Ginsenoside Rh2 and Its Octyl Ester Derivative Inhibited Invasion and Metastasis of Hepatocellular Carcinoma Via the C-Jun/cox2/pge2 Pathway.

Ginsenoside Rg5 Induces Apoptosis in Human Esophageal Cancer Cells Through the Phosphoinositide‑3 Kinase/protein Kinase B Signaling Pathway

Ginsenoside Rh3 Inhibits Lung Cancer Metastasis by Targeting Extracellular Signal-Regulated Kinase: A Network Pharmacology Study

Ginsenoside Rb1 Inhibits Hypoxia-Induced Epithelial-Mesenchymal Transition in Ovarian Cancer Cells by Regulating Microrna-25

Ginsenoside Rh1 Prevents Migration and Invasion through Mitochondrial ROS-Mediated Inhibition of STAT3/NF-κB Signaling in MDA-MB-231 Cells

The Preparation of Ginsenoside Rg5, Its Antitumor Activity Against Breast Cancer Cells and Its Targeting of PI3K.

20(S)-ginsenoside Rh2 as agent for treatment of LMN-CRC via regulating epithelial-mesenchymal transition.

Ginsenoside 20(S)-Rg3 Targets HIF-1α to Block Hypoxia-Induced Epithelial-Mesenchymal Transition in Ovarian Cancer Cells